目的 探讨芪蛭降糖胶囊联合利格列汀片治疗2型糖尿病的临床疗效。方法 选取2018年2月-2019年2月在深圳市龙华区中心医院治疗的2型糖尿病患者88例，根据入院的先后分为对照组（44例）和治疗组（44例）。对照组口服利格列汀片，5 mg/次，1次/d；治疗组在对照组基础上口服芪蛭降糖胶囊，2.5 g/次，3次/d。两组患者均治疗4周。观察两组患者临床疗效，同时比较治疗前后两组患者空腹血糖（FBG）、餐后2 h血糖（2 h PG）、糖化血红蛋白（HbA1c）、胰岛素（FINS）、血糖波动标准差（SDBG）、全天平均血糖波动幅度（MAGE）、全天有效血糖波动次数（NGE）、日间血糖平均绝对差（MODD）、HOMA-β、HOMA-IR及血清单核细胞趋化蛋白-1（MCP-1）、富含半胱氨酸的酸性分泌蛋白（SPARC）、转化生长因子-β1（TGF-β1）、血管细胞粘附分子-1（VCAM-1）和人颗粒蛋白前体（PGRN）水平。结果 治疗后，对照组和治疗组临床有效率分别为81.82%和97.73%，两组比较差异有统计学意义（P<0.05）。经治疗，两组患者FPG、2 h PG、HbAlc、FINS水平均明显下降（P<0.05），且治疗组患者FPG、2 h PG、HbAlc、FINS水平明显低于对照组（P<0.05）。经治疗，两组患者SDBG、MAGE、NGE、MODD值均明显减小（P<0.05），且治疗组患者SDBG、MAGE、NGE、MODD值明显小于对照组（P<0.05）。经治疗，两组患者HOMA-β明显升高（P<0.05），HOMA-IR明显降低（P<0.05），且治疗组患者HOMA-β和HOMA-IR值明显优于对照组（P<0.05）。经治疗，两组患者血清MCP-1、SPARC、TGF-β1、VCAM-1、PGRN水平均显著降低（P<0.05），且治疗组患者这些血清学指标水平明显低于对照组（P<0.05）。结论 芪蛭降糖胶囊联合利格列汀片治疗2型糖尿病能够有效控制患者血糖，降低促炎因子水平，促进胰岛素抵抗的改善和提高胰岛素敏感性。

Objective To explore the clinical effect of Qizhi Jiangtang Capsules combined with ligliptin in treatment of type 2 diabetes mellitus. Methods Patients (88 cases) with type 2 diabetes mellitus in Shenzhen Longhua District Central Hospital from February 2018 to February 2019 were divided into control (47 cases) and treatment (47 cases) groups based on visiting sequence. Patients in the control group were po administered with Linagliptin Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Qizhi Jiangtang Capsules on the basis of the control group, 2.5 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, and FBG, 2 h PG, HbA1c, FINS, SDBG, MAGE NGE MODD, HOMA-β, HOMA-IR, and the serum levels of MCP-1, SPARC, TGF-β1, VCAM-1, and PGRN in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 81.82% and 97.73% respectively, and there were differences between two groups (P<0.05). After treatment, the FPG, 2 h PG, HbAlc and FINS in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the SDBG, MAGE, NGE and MODD value in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the HOMA-β in two groups was significantly increased (P<0.05), but HOMA-IR was significantly decreased (P<0.05), and the HOMA-β and HOMA-IR value in the treatment group were significantly better than that in the control group (P<0.05). After treatment, the serum levels of MCP-1, SPARC, TGF-β1, VCAM-1, and PGRN in two groups were significantly decreased (P<0.05), and these indexes in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Qizhi Jiangtang Capsules combined with ligliptin in treatment of type 2 diabetes mellitus can effectively control blood sugar, reduce the level of proinflammatory factors, improve insulin resistance and increase insulin sensitivity.